Phase 2 Multiple Sclerosis Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing and able to give written consent before any assessments are carried out.
- People who have been diagnosed with relapsing remitting multiple sclerosis and have had the disease for less than 15 years.
- People aged 18 to 55 years (inclusive), male or female.
- Women must meet one of the following conditions related to pregnancy prevention: have been through menopause for at least one year; have had a surgical procedure that prevents pregnancy (such as a hysterectomy, removal of both ovaries, or tubal ligation), or have a male partner who has had a vasectomy; be using a highly effective form of birth control if sexually active (such as hormonal contraceptives, an IUD, a contraceptive patch or injection, or a double barrier method); not be heterosexually active at the time of joining (though if this changes during the trial, a highly effective birth control method would be required); or be practicing true abstinence as a consistent lifestyle choice (note: methods that only avoid sex on certain days are not accepted).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose recent MRI scan shows significant shrinkage of the brain for their age, as assessed by a specialist radiologist or the lead investigator.
- People who have a new lesion (area of damage) visible on an MRI taken within the past 3 months.
- People who have had an allergic reaction to clemastine, similar antihistamine medicines, or any of the ingredients in the trial medication.
- People who have been treated with corticosteroid medicines within the 30 days before the screening visit.
- People with a disability score of 4.5 or higher on the standard MS disability scale (EDSS) (confirm with trial site).
- People with a history of significant problems with the heart's electrical conduction system.
- People with a history of cancer.
- People who have had thoughts of suicide or suicidal behaviour in the 6 months before the start of the trial.
- People who are pregnant, breastfeeding, or planning to become pregnant.
- People who are currently participating in another research study at the same time, without prior approval.
- People who are currently using any other therapy aimed at repairing the myelin (protective nerve coating), as determined by the investigator.
- People who have previously been treated with total lymphoid irradiation, or T cell or T cell receptor vaccination.
- People who have previously been treated with alemtuzumab, mitoxantrone, or cyclophosphamide.
- People whose recent blood test results (reported within 72 hours) show certain abnormal kidney or liver markers above specified levels (confirm exact values with trial site).
- People with a history of drug or alcohol misuse within the past year.
- People with untreated vitamin B12 deficiency or untreated underactive thyroid, as determined by blood tests.
- People with significant ongoing medical conditions affecting the heart, metabolism, blood, liver, immune system, kidneys, lungs, nervous system, mental health, skin, or other major body systems, where the lead investigator believes this could affect the safety of the participant or the reliability of the study results.
- People with a significant medical condition or abnormal test result that, in the investigator's opinion, would prevent safe participation in the study.
- People who are unable to have an MRI scan, including those with severe claustrophobia.
- People who have dental braces or any permanent or non-removable metal in the jaw or face.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If you need support right now
This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.
If you or someone else is in immediate danger, call 000.
- Lifeline — 24/7 crisis support: 13 11 14
- Suicide Call Back Service — 24/7 counselling: 1300 659 467
- 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
- Beyond Blue — 24/7 mental health support: 1300 22 4636
- Emergency: 000
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.
Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Principal Investigator: Ari J Green, MD, University of California, San Francisco
Phone: 415-745-1304
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Corpus Callosum Myelin Water Fraction; Change from Baseline in Corpus Callosum Myelin Water Fraction at 3 Months; Change from Baseline in Corpus Callosum Myelin Water Fraction at 6 Months; Corpus Callosum T1 Relaxation Time; Change from Baseline in Corpus Callosum T1 Relaxation Time at 3 Months; Change from Baseline in Corpus Callosum T1 Relaxation Time at 6 Months; Corpus Callosum UTE Fraction; Change from Baseline in Corpus Callosum UTE Fraction at 3 Months; Change from Baseline in Corpus Callosum UTE Fraction at 6 Months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.